Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Abstract

In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. (Funded by Agios Pharmaceuticals; ClinicalTrials.gov number, NCT02074839 .).

Keywords

Affiliated Institutions

• Sarah Cannon US
• UCSF Helen Diller Family Comprehensive Cancer Center US
• Mayo Clinic Hospital US
• Northwestern University PH
• Sylvester Comprehensive Cancer Center US
• City Of Hope National Medical Center US
• University of Alabama at Birmingham US
• Mayo Clinic in Florida US
• Emory University US
• The University of Texas MD Anderson Cancer Center US
• Jacksonville College US
• Cleveland Clinic US
• University of Miami US
• Massachusetts General Hospital US
• Sarah Cannon Research Institute GB
• The Ohio State University Wexner Medical Center US
• Institut Gustave Roussy FR
• Agios Pharmaceuticals (United States) US
• University of Colorado Denver US
• Dana-Farber Cancer Institute US
• The University of Texas Southwestern Medical Center US
• Cancer Institute (WIA) IN
• Cornell University US
• Johns Hopkins University US
• Oregon Health & Science University US
• University of California, San Francisco US
• Centre Hospitalier Universitaire de Bordeaux FR
• Memorial Sloan Kettering Cancer Center US
• Washington University in St. Louis US
• Medical University of South Carolina US
• MUSC Hollings Cancer Center US
• WinnMed US

Related Publications